Cellular Therapies: Revolutionizing Cancer Therapy, Part 4: Adoptive Cell Therapy - Lessons Learned, Issues and the Future

In this, the final video in this four-part series, Carl June, MD, reviews the challenges identified with CAR T cell therapy in the hematologic malignancies--including resistance and early relapse in some patients and toxicities (i.e., tumor lysis syndrome, cytokine release syndrome) --as well as the progress made to resolve or ameliorate these concerns and future considerations for the therapy.

To view other parts of this program:

Part 1: Adoptive Cell Therapy - An Introduction

Part 2: CTL019 Therapy in Chronic Lymphocytic Leukemia

Part 3: CTL019 in Relapsed Refractory Pediatric Acute Lymphoblastic Leukemia

 

 

Related Links

• Clinical Briefing: Enrolling Clinical Trials: Adoptive Immunotherapy for Chemotherapy Resistant or Refractory CD-19+ Leukemia and Lymphoma
• Case Study: A 65-year-old male is treated with CD-19 chimeric antigen receptor T-cell therapy for purine-refractory CLL
• Dr. June’s Profile